Verification evidence is still being completed.
PDF / print export
Biotts S.A.
Wroclaw, Poland
- Verified lead
- Jan Henk Hendriks
- Lead status
- STATUS: VERIFIED APRIL 2026
- Leadership verification
- Chief Executive Officer
- 2026 technical specialization
- Transdermal Drug Delivery, MTC-Y Carrier Technology, Insulin, Oncology, and Diabetes Formulations
- Review cycle
- 24 April 2026
- Full address
- ul. Dunska 7, Wroclaw Technology Park (Omega building), 54-427 Wroclaw, Poland
- Site coordinates
- Verification evidence is still being completed.
- Editorial review
- Memel Biotech editorial review
- Official leadership source
- Biotts official site naming Jan Henk Hendriks as Chief Executive Officer.
- Editorial note
- Wroclaw transdermal drug-delivery biotech with named CEO, proprietary MTC-Y carrier platform, and first-in-world transdermal insulin delivery program backed by a BIOTON partnership.
Transdermal Drug Delivery, MTC-Y Carrier Technology, Insulin, Oncology, and Diabetes Formulations
Wroclaw Technology Park tenancy, BIOTON partnership, Public CEO disclosure
Wroclaw transdermal drug-delivery biotech with named CEO, proprietary MTC-Y carrier platform, and first-in-world transdermal insulin delivery program backed by a BIOTON partnership.
Review coverage
Leadership
Facility
Certifications
Capabilities
Partners
Sources
Quality
Editorial verificationMemel Biotech directory review sign-off
Report generated05 Jun 2026, 01:06
Company profile · Wroclaw, Poland
Biotts S.A.
Transdermal Drug Delivery, MTC-Y Carrier Technology, Insulin, Oncology, and Diabetes Formulations · Transdermal drug-delivery R&D
Verified 24 Apr 2026 · 3 sources
Wroclaw transdermal drug-delivery biotech with named CEO, proprietary MTC-Y carrier platform, and first-in-world transdermal insulin delivery program backed by a BIOTON partnership.
Contact & location
- Website
- biotts.com
- Company page
- Lead
- Jan Henk Hendriks (verified ↗)
- Compliance
- Not yet on record
- Last reviewed
- 24 Apr 2026 (1mo ago)
- Scale
- Transdermal drug-delivery R&D
- Capabilities
- MTC-Y Multifunctional Transdermal Carrier · Transdermal Insulin Delivery · Oncology and Diabetes Transdermal Formulations
- Founded
- 2014
- Headcount
- 11-50
Clinical profileSTATUS: VERIFIED APRIL 2026
Jan Henk Hendriks
Chief Executive Officer
Full addressul. Dunska 7, Wroclaw Technology Park (Omega building), 54-427 Wroclaw, Poland
Site coordinatesVerification evidence is still being completed.
Review cycle24 April 2026
Transdermal drug-delivery R&D
Wroclaw, Poland. Transdermal Drug Delivery, MTC-Y Carrier Technology, Insulin, Oncology, and Diabetes Formulations. Review completed on 24 Apr 2026.
Polish Office for Registration of Medicinal Products and EMA for future clinical oversight
Wroclaw Technology Park tenancy, BIOTON partnership, Public CEO disclosure
Transdermal Drug Delivery, MTC-Y Carrier Technology, Insulin, Oncology, and Diabetes Formulations
Wroclaw transdermal drug-delivery biotech with named CEO, proprietary MTC-Y carrier platform, and first-in-world transdermal insulin delivery program backed by a BIOTON partnership.
Editorial note
Biotts is a Wroclaw transdermal drug-delivery biotech with a named CEO, a proprietary MTC-Y carrier, the industry's first documented transdermal insulin delivery, and an active BIOTON partnership.
FULL TRUST REVIEW COMPLETE
Shown only when all seven trust checks are fully mapped in the directory.
Current review cycleApril 2026
Capabilities
Core capabilities
Primary declared technical activities and areas of operating focus.
MTC-Y Multifunctional Transdermal Carrier
Transdermal Insulin Delivery
Oncology and Diabetes Transdermal Formulations
Verification source dossier
Verification source dossier
Official source set used to support leadership, physical-site, certification, and watch-note evidence.
Infrastructure
Declared infrastructure
MTC-Y transdermal carrier development
Transdermal insulin formulation
Wroclaw Technology Park facilities
Regulatory posture
Quality system coverage
GMP / GLP / ISO-13485 / FDA-Inspected are global quality-system standards. "Verified active" means the directory confirmed the certification is current; "Review in progress" means the cert status is currently being re-verified.
- GMP
- REVIEW IN PROGRESS 2026
- GLP
- REVIEW IN PROGRESS 2026
- ISO-13485
- REVIEW IN PROGRESS 2026
- FDA-Inspected
- REVIEW IN PROGRESS 2026
Verification history
Verification history
24 Apr 2026: Executive identity confirmed via official management disclosure.
24 Apr 2026: Full trust review completed.
FAQ
Frequently asked questions
- Where is Biotts S.A. located?
- Biotts S.A. operates from ul. Dunska 7, Wroclaw Technology Park (Omega building), 54-427 Wroclaw, Poland, Wroclaw, Poland.
- Who runs Biotts S.A.?
- Biotts S.A. is led by Jan Henk Hendriks, Chief Executive Officer. Verified 24 Apr 2026.
- What does Biotts S.A. do?
- Wroclaw transdermal drug-delivery biotech with named CEO, proprietary MTC-Y carrier platform, and first-in-world transdermal insulin delivery program backed by a BIOTON partnership. Core capabilities: MTC-Y Multifunctional Transdermal Carrier, Transdermal Insulin Delivery, Oncology and Diabetes Transdermal Formulations.
Editorial context
Related technical briefs
Briefs that name Wroclaw as a covered market or city.